Citadel Advisors
NUVB icon

Citadel Advisors’s Nuvation Bio NUVB Stock Holding History

Citadel Advisors’s Portfolio NUVB Stock Details NUVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$567K Sell
99,800
-66,200
-40% -$324K ﹤0.01% 9551
2026
Q1 		$712K Sell
166,000
-179,100
-52% -$998K ﹤0.01% 8456
2025
Q4 		$3.09M Buy
345,100
+17,400
+5% +$108K ﹤0.01% 5099
2025
Q3 		$1.21M Buy
327,700
+220,900
+207% +$602K ﹤0.01% 7122
2025
Q2 		$208K Sell
106,800
-46,700
-30% -$97.3K ﹤0.01% 10591
2025
Q1 		$270K Sell
153,500
-69,600
-31% -$158K ﹤0.01% 9821
2024
Q4 		$593K Buy
223,100
+124,400
+126% +$320K ﹤0.01% 8182
2024
Q3 		$226K Buy
98,700
+92,200
+1,418% +$281K ﹤0.01% 9898
2024
Q2 		$19K Buy
6,500
+3,600
+124% +$11K ﹤0.01% 12694
2024
Q1 		$10.6K Buy
2,900
+2,500
+625% +$4.8K ﹤0.01% 13453
2023
Q4 		$604 Buy
400
+200
+100% +$257 ﹤0.01% 13990
2023
Q3 		$268 Buy
+200
New +$333 ﹤0.01% 14102
2021
Q3 		– Sell
-38,500
Closed -$358K – 14393
2021
Q2 		$358K Buy
+38,500
New +$439K ﹤0.01% 10839

Other funds holding NUVB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OFM
Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
DFO
Duquesne Family Office New York $5.21B AUM 87.01% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Citadel Advisors's NUVB Position: Q2 2026 in Review

Citadel Advisors reduced its Nuvation Bio (NUVB) stake by 3.7% in Q2 2026, selling an estimated $377K and leaving 1,988,330 shares worth $11.3M. The position accounts for ﹤0.01% of the portfolio, ranked #3386.

Citadel Advisors first reported a position in NUVB in Q4 2020 and has held it in 23 quarters since. The position peaked at $68.8M in Q1 2021. 244 funds tracked by Wall St. Rank hold NUVB as of Q2 2026.

  • Citadel Advisors held 1,988,330 shares of Nuvation Bio worth $11.3M as of Q2 2026.
  • Citadel Advisors sold 77,081 Nuvation Bio shares in Q2 2026, an estimated $377K.
  • Nuvation Bio made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #3386 holding.
  • Citadel Advisors first reported a position in Nuvation Bio in Q4 2020 and has held it in 23 quarters since.
  • Citadel Advisors's Nuvation Bio position peaked at $68.8M in Q1 2021.
  • 244 funds tracked by Wall St. Rank held Nuvation Bio as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.